http://orcid.org/0000-0003-4366-2584
References
- Bedaiwy MA, Abou-Setta AM, Desai N, et al. Gonadotropin-releasing hormone analog cotreatment for preservation of ovarian function during gonadotoxic chemotherapy: a systematic review and meta-analysis. Fertil Steril 2011;95:906–14.e1-4
- Van der Kaaij MA, van Echten-Arends J, Simons AH, et al. Fertility preservation after chemotherapy for Hodgkin lymphoma. Hematol Oncol 2010;28:168–79
- Castelo-Branco C, Nomdedeu B, Camus A, et al. Use of gonadotropin-releasing hormone agonists in patients with Hodgkin’s disease for preservation of ovarian function and reduction of gonadotoxicity related to chemotherapy. Fertil Steril 2007;87:702–5
- Blumenfeld Z, Evron A. Preserving fertility when choosing chemotherapy regimens – the role of gonadotropin-releasing hormone agonists. Expert Opin Pharmacother 2015;16:1009–20
- Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. Cancer Treat Rev 2014;40:675–83
- Harel S, Fermé C, Poirot C. Management of fertility in patients treated for Hodgkin’s lymphoma. Haematologica 2011;96:1692–9
- Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadatrophin suppression to prevent chemotherapy-induced ovarian damage. Obstet Gynecol 2013;121:78–86
- Elgindy E, Sibai H, Abdelghani A, et al. Protecting ovaries during chemotherapy through gonad suppression. Obstet Gynecol 2015;126:187–95
- Angarita AM, Johnson CA, Fader AN, Christianson MS. Fertility preservation: a key survivorship issue for young women with cancer. Front Oncol 2016;6:102
- Zhang Y, Xiao Z, Wang Y, et al. Gonadotropin-releasing hormone for preservation of ovarian function during chemotherapy in lymphoma patients of reproductive age: a summary based on 434 patients. PLoS One 2013;8:e80444
- Lambertini M, Ceppi M, Poggio F, et al. Ovarian suppression using luteinizing hormone releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol 2015;26:2408–19
- Chen H, Li J, Cui T, et al. Adjuvant gonadotropin-releasing hormone analogues for the prevention of chemotherapy induced premature ovarian failure in premenopausal women. Cochrane Database Syst Rev 2011:CD008018
- Moore HC, Unger JM, Phillips KA, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med 2015;372:923–32
- Cuzick J, Ambroisine L, Davidson N, et al. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinizing-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone receptor-positive breast cancer: a meta-analysis of individual patient data from randomised adjuvant trials. Lancet 2007;369:1711–23
- Blumenfeld Z, Patel B, Leiba R, Zuckerman T. Gonadotropin-releasing hormone agonist may minimize premature ovarian failure in young women undergoing autologous stem cell transplantation. Fertil Steril 2012;98:1266–70